Pan-European umbrella organization of scleroderma patient support and advocacy associations. Works to increase awareness, support research, and advocate for equitable treatments across Europe. Registered as an international non-profit (AISBL) in Belgium.
First-in-class oral PDE4B inhibitor approved for adults with IPF and PPF after Phase III trials showed slower lung function decline and a favourable tolerability profile.
